Sofosbuvir and ribavirin therapy for children aged 3 to <12 years with hepatitis C virus genotype 2 or 3 infection | HCV Guidance

HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C

Sofosbuvir and ribavirin therapy for children aged 3 to <12 years with hepatitis C virus genotype 2 or 3 infection

Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin therapy for children aged 3 to <12 years with hepatitis C virus genotype 2 or 3 infection. Hepatology. 2020;71(1):31-43.

Publication Type:

Journal Article

Authors:

Rosenthal, P; Schwarz, KB; Gonzalez-Peralta, RP; et, al

Source:

Hepatology, Volume 71, Issue 1, p.31-43 (2020)

Cited On:

HCV in Children

Export Citation:

RIS Format

Top